Hutchison China MediTech Ltd ADR diskutieren

HCM with several data readouts coming could be catalysts for upside.

The stock offers investors a strong pipeline of differentiated candidates (up to 15 possible Breakthrough Therapy Designations), China exposure (via its sales team of over 3,200 employees and 1,900 medical professionals), validating partnerships and several upcoming catalysts. Downside appears limited due to having several irons in the fire, low cash burn as a result of its prescription drug commercial services segment offsetting clinical costs and quite a few pivotal readouts lined up over the next couple years.

Pharmazeutische SecteurProduits Agenda 12/03 | 08.00 Uhr veröffentlichte Ergebnisse

Hutchison China Meditech wendet sich an die erste Arzneimittelzulassung in diesem Jahr